Featured Research

from universities, journals, and other organizations

New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

Date:
February 8, 2005
Source:
University Of Michigan Health System
Summary:
A new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy with fewer side effects caused tumors to shrink in 95 percent of patients, a new study by researchers at the University of Michigan Comprehensive Cancer Center found.

ANN ARBOR, Mich. -- A new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy with fewer side effects caused tumors to shrink in 95 percent of patients, a new study by researchers at the University of Michigan Comprehensive Cancer Center found.

Patients with advanced-stage follicular lymphoma – a cancer generally considered incurable – who had not been previously treated with any other form of therapy received a single course of treatment with the Bexxar therapeutic regimen, a radioactive antibody injected into the bloodstream that targets and kills cancer cells. Of the 76 patients enrolled in the study, 95 percent responded to the treatment and 75 percent had a complete response, meaning no evidence of cancer remained. More than three-quarters of patients with a complete remission were disease-free after five years.

Results of the study appear in the Feb. 3 New England Journal of Medicine.

"The results of this treatment, which essentially takes only one week to complete, rival any kind of treatment that's been used for follicular lymphoma, including chemotherapy regimens that take months to complete. It's very well-tolerated by patients and we saw complete remission in the majority of patients lasting for years," says lead study author Mark Kaminski, M.D., director of the Leukemia/Lymphoma Program and the Multidisciplinary Lymphoma Clinic at the U-M Comprehensive Cancer Center.

Kaminski and his colleague Richard Wahl (formerly at U-M and now at Johns Hopkins University) developed the Bexxar regimen, which received approval from the U.S. Food and Drug Administration in June 2003 to treat follicular non-Hodgkin's lymphoma after other treatments have failed. The newly published research involves Bexxar as a first-line treatment for this disease.

Non-Hodgkin's lymphoma, the nation's sixth leading cause of cancer death, is a cancer of the lymph system, which is part of the immune system. Lymphoma spreads easily through the lymph system and the bloodstream and consequently tends to be widespread when it is diagnosed. Traditional treatment often involves intensive chemotherapy, or a combination of chemotherapy and the monoclonal antibody rituximab. These treatments are usually given every three weeks over a span of up to six months and can cause many unpleasant side effects, including nausea, hair loss and infections.

Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma and is not considered to be curable using these traditional treatments; even after patients initially have a response to treatment, the disease almost always comes back and becomes more difficult to treat.

Bexxar, whose chemical name is tositumomab and iodine I 131 tositumomab, combines an antibody that seeks out cancer cells, and a radioactive form of the element iodine. When injected, it travels like a guided missile through the bloodstream to bind to a protein found on the surface of the cancerous cells. The radiation zaps these malignant cells with minimal exposure to normal tissues.

With the Bexxar therapeutic regimen, a patient receives an injected test dose of radioactive Bexxar to determine how that patient's body processes the tagged antibody. Nuclear medicine scans are used to assess how quickly Bexxar reaches the tumor and how quickly the radiation disappears from the patient's body. One to two weeks after that initial dose, the patient then receives a custom-tailored therapeutic dose, and therapy is considered complete. The most common side effect is a temporary lowering of blood counts several weeks after the treatment. There is no hair loss and nausea is rare.

Results from this study are even more promising than results using Bexxar after other therapies have failed. In those studies, 70 percent of patients responded to Bexxar and 20 percent to 30 percent saw a complete remission. Bexxar is marketed in the United States by GlaxoSmithKline.

"Given how much better this treatment worked as first-line therapy in our study, moving this treatment up earlier in the course of a patient's illness should be strongly considered instead of using it as a last resort or not at all. These results support the notion that there's a real possibility of putting chemotherapy on the back burner for this disease," says Kaminski, a professor of internal medicine at the U-M Medical School. "New studies can now be designed to begin to test this possibility," he adds.

In addition to Kaminski, U-M study authors are Melissa Tuck, research associate for Hematology/Oncology; Judith Estes, M.S.N., N.P., nurse practitioner in the lymphoma clinic; Charles W. Ross, M.D., associate professor of Pathology; Kenneth Zasadny, Ph.D., Nuclear Medicine; Denise Regan and Paul Kison, nuclear medicine technicians; Susan Fisher, project associate in Radiology. Other authors are Stewart Kroll from Corixa Corp.; Arne Kolstad, M.D., Ph.D., from the Norwegian Radium Hospital, Oslo; and Richard L. Wahl, M.D., from Johns Hopkins University School of Medicine.

###

Funding for the study was from the National Cancer Institute, the National Institutes of Health and Corixa. The University of Michigan holds patents for the Bexxar therapeutic regimen, which is marketed by GlaxoSmithKline under a licensing agreement. U-M receives royalties on sales of Bexxar, a portion of which goes to Kaminski and his co-inventors.

For information about non-Hodgkin's lymphoma, visit http://www.cancer.med.umich.edu/learn/lymphomainfo.htm or call the Cancer AnswerLine at 800-865-1125. For information about Bexxar from its manufacturer, call 877-4-BEXXAR.

Reference: New England Journal of Medicine, Vol. 352, No. 5, pp. 441-449


Story Source:

The above story is based on materials provided by University Of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan Health System. "New Treatment Rivals Chemotherapy For Lymphoma, Study Finds." ScienceDaily. ScienceDaily, 8 February 2005. <www.sciencedaily.com/releases/2005/02/050205080055.htm>.
University Of Michigan Health System. (2005, February 8). New Treatment Rivals Chemotherapy For Lymphoma, Study Finds. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2005/02/050205080055.htm
University Of Michigan Health System. "New Treatment Rivals Chemotherapy For Lymphoma, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2005/02/050205080055.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins